Tag: Bright Minds Biosciences - Psychedelic Alpha

Our 2022 Year in Review is now live.

Read more about the article Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

Post published:February 27, 2023
Post category:Press Release

Read more about the article Bright Minds Biosciences Announces Non-Executive Director Appointment

Bright Minds Biosciences Announces Non-Executive Director Appointment

Post published:February 17, 2023
Post category:Press Release

Read more about the article Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements

Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements

Post published:February 8, 2023
Post category:Press Release

Read more about the article Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Post published:January 28, 2023
Post category:Press Release

Read more about the article Bright Minds Biosciences Announces Resignation of Board Member

Bright Minds Biosciences Announces Resignation of Board Member

Post published:January 12, 2023
Post category:Press Release

Read more about the article Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement

Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement

Post published:December 2, 2022
Post category:Press Release

Read more about the article Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors

Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors

Post published:September 8, 2022
Post category:Press Release

Read more about the article Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome

Post published:August 31, 2022
Post category:Press Release

Read more about the article Bright Minds Biosciences Announces Closing of $4 Million Unit Offering

Bright Minds Biosciences Announces Closing of $4 Million Unit Offering

Post published:August 31, 2022
Post category:Press Release

Read more about the article Bright Minds Biosciences Comments on Recent Trading Activity

Bright Minds Biosciences Comments on Recent Trading Activity

Post published:August 18, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.